Overview

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Status:
RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Treatments:
Carboplatin
Paclitaxel